Abstract: The present invention relates to albumin as an active ingredient in a medicament for the treatment of cancer and to a pharmaceutical composition comprising at least one anti-neoplastic agent and albumin at a concentration of at least 2% w/v of the composition, in a pharmaceutically acceptable vehicle. The anti-neoplastic agent is preferably hydroxyurea, preferably at concentration between 10 ?M and 1 mM, more preferably between 10 ?M and 100 ?M. The pharmaceutical composition of the invention is effective in the therapeutic treatment of cancer and advantageously shows reduced side effects in comparison with the administration of the anti-neoplastic agent alone.

Abstract: The invention relates to cell lines from differentiated cells with hepatocytic phenotypes capable of producing albumin and blood coagulation factors, said cells being derived from a human leukaemia cell line, preferably the human THP1 cell line, and preserving the characteristics of immortality. Among the cell lines of the invention, the cell lines known as PSC-THP1-EP, PSC-THP1-EP-FAST, PSC-THP1-HEP and PSC-THP1-EPEP are preferred. The invention also relates to methods for obtaining the cell lines of the invention and the uses of said cell lines, particularly for the production of albumin and/or blood coagulation factors.